- Home
- Equipment
- australasia
- tumor cells
Show results for
Refine by
Tumor Cells Equipment Supplied In Australasia
22 equipment items found
Manufactured by:INOVIQ Ltd based inNotting Hill, AUSTRALIA
In initial clinical studies, SubB2M has detected cancers with 100% sensitivity and specificity for mid to late-stage cancers, and >95% specificity and 100% sensitivity for early-stage cancers. There is also evidence that Neu5Gc is present in a wide range of solid human tumors and can be detected in serum using SubB2M. SubB2M has the potential to detect cancer using liquid ...
Manufactured by:Cartherics Pty ltd based inNotting Hill, AUSTRALIA
Indication: Other TAG-72* tumors. Research: iNK cells [TAG-72 CAR + gene KO]. ...
Manufactured by:Cartherics Pty ltd based inNotting Hill, AUSTRALIA
Indication: Solid tumors. Research: iT cells and macrophages [CARs+/- gene KOs]. ...
Manufactured by:Cartherics Pty ltd based inNotting Hill, AUSTRALIA
Indication: Solid tumors. Research: Descriptor iNK cells [other CAR targets / dual ...
Manufactured by:Cartherics Pty ltd based inNotting Hill, AUSTRALIA
Indication: Solid tumors. Research: CAR iNK cells + novel receptor fusion proteins. ...
Manufactured by:Cartherics Pty ltd based inNotting Hill, AUSTRALIA
Indication: Ovarian Cancer. Research: iNK cells [TAG-72 CAR + gene ...
Manufactured by:Radiopharm Theranostics based inCarlton, AUSTRALIA
PSA-mAb is the invention of Professor David Ulmert formerly of Memorial Sloan Kettering and now ...
by:Chimeric Therapeutics based inCarlton South, AUSTRALIA
The CORE-NK platform is a transformative platform technology for Chimeric enabling the accelerated development of multiple next generation, off the shelf NK and CAR-NK products. Natural killer cells are found in our bodies naturally and are able to recognize and kill cancer cells – but are not robust and active enough to overcome cancer as it grows. CORE-NK platform cells are made by ...
Manufactured by:Cartherics Pty ltd based inNotting Hill, AUSTRALIA
This technology arms the patient’s own T cells with CARs, which enable them to “seek and destroy” cancer ...
Manufactured by:INOVIQ Ltd based inNotting Hill, AUSTRALIA
INOVIQ has developed a proprietary immunocytochemistry (ICC) assay that detects hTERT, a component of telomerase, which is upregulated in most human epithelial ...
Manufactured by:Radiopharm Theranostics based inCarlton, AUSTRALIA
PTPµ (PTPmu) is a peptide molecule biomarker, invented by Dr Susann Brady-Kalnay at Case Western Reserve University in Ohio. ...
Manufactured by:Biosceptre International Limited based inCambridge, UNITED KINGDOM
nfP2X7 is a tumour-specific form of the P2X7 ligand-gated ion channel, consisting of three identical protein subunits. When exposed to high concentrations of extracellular adenosine triphosphate (ATP), P2X7 forms a channel, driving a range of diverse physiological functions including proliferation and immune cell functions. Under prolonged stimulation, P2X7 can form a membrane pore that’s ...
Manufactured by:Biosceptre International Limited based inCambridge, UNITED KINGDOM
CAR T-cell therapy is the engineering of a patient’s T cells, a type of white blood cell. A small portion of these cells are collected, from a patient’s blood sample, and re-engineered to produce chimeric antigen receptors (CAR’s) on the cell surface. The chimeric antigen receptors give T cells the ability to target cancer cells. They comprise two specific components: one, an ...
Manufactured by:Radiopharm Theranostics based inCarlton, AUSTRALIA
DUNP19 is the invention of Professor Ulmert at UCLA. ...
Manufactured by:Cartherics Pty ltd based inNotting Hill, AUSTRALIA
This technology involves induced pluripotential stem cell (iPSC) derived NK cells (and, potentially, other types of immune cells). iPSCs have unlimited capacity for ...
Manufactured by:Biosceptre International Limited based inCambridge, UNITED KINGDOM
We are also developing antibodies that specifically target nfP2X7 for use in both solid and haematological tumours. Our preclinical data is very promising and studies show an excellent safety profile. By exploiting the modular nature of the antibody structure, the same panel of antibody sequences can be used to generate a variety of therapeutic antibody formats including, but not limited to, ...
by:Carina Biotech based inMawson Lakes, AUSTRALIA
Advanced colorectal cancer currently has a poor prognosis and is the deadliest form of cancer for Australians 25 to 34 years old. LGR5 is a cancer stem cell marker that is highly expressed on advanced colorectal cancer and other cancers. In colon cancer patients, LGR5+ expression has been correlated with a particularly poor ...
by:Chimeric Therapeutics based inCarlton South, AUSTRALIA
CHM 2101 (CDH17 CAR T) is an optimized 3rd generation CAR T cell therapy that is the first to target ...
by:AdAlta Limited based inBundoora, AUSTRALIA
AdAlta and Carina Biotech to develop next-generation i-body enabled CAR-T cancer therapeutics. AdAlta has entered a collaboration agreement with Carina Biotech to develop next-generation i-body enabled CAR-T cells, with the potential to bring CAR-T cell therapy to treat a far greater range of cancers than the small number of blood cancers that has been achieved today. Under the Collaboration ...
Manufactured by:Agilent Technologies, Inc. based inSanta Clara, CALIFORNIA (USA)
The SureGuide gRNA Synthesis Kit is part of an integrated solution for in-vitro CRISPR/Cas research. Use this kit to generate high concentrations of gRNA, and combine with the SureGuide Cas9, or your own Cas9 protein, to clone complex genomic regions with high accuracy and specificity. The SureGuide gRNA kit shortens your time from planning to experiment, and reduces the cost of setting up your ...